Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
Anti-IL-5 receptor monoclonal antibody
Asthma
Benralizumab
Eosinophilic chronic rhinosinusitis
Eosinophilic otitis media
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
04
2020
revised:
16
06
2020
accepted:
16
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
Eosinophilic chronic rhinosinusitis (ECRS) is characterized by the presence of nasal polyps, dominant ethmoid shadows in computed tomography (CT) scans, and elevated levels of eosinophil infiltration into the nasal polyps and peripheral blood. ECRS is often accompanied by severe asthma. The recent development of monoclonal antibody-based biologics, including benralizumab, has offered new therapeutic approaches for the treatment of asthma and allergic diseases. Asthma and ECRS are closely related; hence, benralizumab could provide clinical benefit in ECRS patients with severe asthma. Herein, we report a case of a 47-year-old female patient with severe asthma that presented with nasal obstruction and hearing impairment. Nasal endoscopic and otoscopic examinations indicated the presence of bilateral nasal polyps in the middle nasal meatus, as well as a bilateral effusion in the tympanic cavity. Sinus and temporal CT images showed dominant ethmoid sinus and tympanic cavity shadows. Biopsy of nasal polyps revealed high numbers of eosinophils, which led to the diagnosis of ECRS; eosinophilic otitis media (EOM) with hypereosinophilia was also suspected. Treatment with benralizumab reduced the number of peripheral blood eosinophils and improved asthma symptoms. Prolonged benralizumab administration also resulted in a remarkable size reduction in bilateral middle nasal polyps and aeration of the tympanic cavity. In conclusion, benralizumab treatment improved the symptoms of severe asthma, ECRS, and EOM. Eosinophil depletion could be an important mechanism by which benralizumab improves ECRS and EOM. The use of benralizumab for the treatment of ECRS and EOM patients with severe asthma merits further investigation in large-cohort studies.
Identifiants
pubmed: 32612919
doi: 10.1016/j.rmcr.2020.101135
pii: S2213-0071(20)30192-1
pii: 101135
pmc: PMC7322358
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101135Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Allergy. 2015 Aug;70(8):995-1003
pubmed: 25945591
Clin Exp Allergy. 2012 May;42(5):712-37
pubmed: 22092535
Eur Ann Allergy Clin Immunol. 2019 Sep 16;51(5):213-221
pubmed: 30983308
J Inflamm (Lond). 2016 Apr 06;13:11
pubmed: 27053925
Otol Neurotol. 2020 Feb;41(2):e238-e240
pubmed: 31923159
Allergol Int. 2015 Apr;64(2):121-30
pubmed: 25838086
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1379-1392
pubmed: 31076056
Allergol Int. 2020 Apr;69(2):178-186
pubmed: 32139163
Exp Mol Med. 2013 Mar 08;45:e14
pubmed: 23470716
Clin Mol Allergy. 2019 Feb 13;17:3
pubmed: 30804712
Ther Clin Risk Manag. 2018 Oct 23;14:2059-2068
pubmed: 30425502
Curr Allergy Asthma Rep. 2015 Dec;15(12):76
pubmed: 26546407
J Allergy Clin Immunol Pract. 2019 Feb;7(2):589-596.e3
pubmed: 30193936
Curr Allergy Asthma Rep. 2016 Jul;16(8):54
pubmed: 27393701
Clin Rev Allergy Immunol. 2019 May 10;:
pubmed: 31073812
Clin Transl Allergy. 2020 Jan 3;10:1
pubmed: 31908763
Int Forum Allergy Rhinol. 2016 May;6(5):472-7
pubmed: 26679299
J Investig Allergol Clin Immunol. 2019 Apr;29(2):84-93
pubmed: 31017107
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14
pubmed: 28687232
Medicina (Kaunas). 2019 Jul 03;55(7):
pubmed: 31277327